UBS Group AG Raises Holdings in LENZ Therapeutics, Inc. $LENZ

UBS Group AG increased its stake in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) by 30.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,571,738 shares of the company’s stock after buying an additional 370,122 shares during the quarter. UBS Group AG owned about 0.05% of LENZ Therapeutics worth $25,148,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in LENZ. Versant Venture Management LLC acquired a new stake in LENZ Therapeutics in the third quarter valued at about $123,758,000. First Light Asset Management LLC acquired a new stake in LENZ Therapeutics in the third quarter valued at about $32,282,000. Adage Capital Partners GP L.L.C. lifted its position in LENZ Therapeutics by 108.8% in the second quarter. Adage Capital Partners GP L.L.C. now owns 1,122,738 shares of the company’s stock valued at $32,907,000 after purchasing an additional 585,000 shares during the period. Franklin Resources Inc. lifted its position in LENZ Therapeutics by 6,756.1% in the third quarter. Franklin Resources Inc. now owns 587,084 shares of the company’s stock valued at $27,346,000 after purchasing an additional 578,521 shares during the period. Finally, Aberdeen Group plc lifted its position in shares of LENZ Therapeutics by 274.4% during the 4th quarter. Aberdeen Group plc now owns 489,432 shares of the company’s stock valued at $7,831,000 after acquiring an additional 358,706 shares during the period. Institutional investors and hedge funds own 54.32% of the company’s stock.

LENZ Therapeutics Price Performance

Shares of NASDAQ LENZ opened at $10.06 on Monday. LENZ Therapeutics, Inc. has a 52-week low of $8.25 and a 52-week high of $50.40. The firm has a fifty day moving average of $10.49 and a 200-day moving average of $17.50. The stock has a market capitalization of $315.38 million, a PE ratio of -3.58 and a beta of 0.62.

LENZ Therapeutics (NASDAQ:LENZ) last announced its quarterly earnings data on Tuesday, March 24th. The company reported ($1.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.91) by ($0.25). The firm had revenue of $1.59 million for the quarter, compared to the consensus estimate of $3.09 million. Equities research analysts expect that LENZ Therapeutics, Inc. will post -3.91 EPS for the current fiscal year.

Analysts Set New Price Targets

LENZ has been the subject of a number of research reports. HC Wainwright reduced their price target on shares of LENZ Therapeutics from $56.00 to $48.00 and set a “buy” rating for the company in a research report on Tuesday, April 21st. Weiss Ratings downgraded shares of LENZ Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, April 21st. Citigroup lowered their target price on shares of LENZ Therapeutics from $52.00 to $26.00 and set a “buy” rating for the company in a research note on Thursday, March 26th. Bank of America lowered their price objective on shares of LENZ Therapeutics from $35.00 to $29.00 and set a “buy” rating for the company in a research note on Wednesday, March 25th. Finally, Wall Street Zen cut shares of LENZ Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, LENZ Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $44.00.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.